BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Neesgaard B, Ruhwald M, Weis N. Inducible protein-10 as a predictive marker of antiviral hepatitis C treatment: A systematic review. World J Hepatol 2017; 9(14): 677-688 [PMID: 28588752 DOI: 10.4254/wjh.v9.i14.677]
URL: https://www.wjgnet.com/1948-5182/full/v9/i14/677.htm
Number Citing Articles
Jean-Baptiste Gorin, David F. G. Malone, Benedikt Strunz, Tony Carlsson, Soo Aleman, Niklas K. Björkström, Karolin Falconer, Johan K. Sandberg. Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infectionScientific Reports 2020; 10(1) doi: 10.1038/s41598-020-58768-z
Caecilia H. C. Sukowati, Riccardo Patti, Devis Pascut, Rusdina B. Ladju, Paola Tarchi, Nunzia Zanotta, Manola Comar, Claudio Tiribelli, Lory S. Crocè. Serum Stem Cell Growth Factor Beta for the Prediction of Therapy Response in Hepatocellular CarcinomaBioMed Research International 2018; 2018: 1 doi: 10.1155/2018/6435482
Yadong Wang, Yangyang Hu, Xing Zhang, Yue Luo, Luyuan Ma, Jingjing Lu, Qianfei Liang, Chengjun Xu, Caiyan Zhao, Calvin Q. Pan. IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus InfectionFrontiers in Public Health 2022; 10 doi: 10.3389/fpubh.2022.911551
Chia-Chi Wang, Kuo-Chih Tseng, I-Shiang Tzeng, Jia-Horng Kao. The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinomaJournal of the Formosan Medical Association 2021; 120(3): 965 doi: 10.1016/j.jfma.2020.10.015
Ashraf Tabll, Reem El Shenawy, Hazem Elsharkawy, Faten Zahran Mohamed. Serum inducible protein-10 chemokine as a biomarker for clearance of HCV with and without treatment in Egyptian patientsHuman Antibodies 2019; 27(4): 265 doi: 10.3233/HAB-190381
Melanie Weber, Vidya Padmanabhan Nair, Tanja Bauer, Martin F. Sprinzl, Ulrike Protzer, Michelle Vincendeau. Increased HERV-K(HML-2) Transcript Levels Correlate with Clinical Parameters of Liver Damage in Hepatitis C PatientsCells 2021; 10(4): 774 doi: 10.3390/cells10040774
Stefania Farcomeni, Sonia Moretti, Caterina Fimiani, Lucia Fontanelli Sulekova, Fenicia Vescio, Leonardo Sernicola, Maria T. Maggiorella, Anna Lisa Remoli, Orietta Picconi, Luciana Mosca, Rozenn Esvan, Elisa Biliotti, Massimo Ciccozzi, Marco Sgarbanti, Gloria Taliani, Alessandra Borsetti. Short- and Long-Term Immunological Responses in Chronic HCV/HIV Co-Infected Compared to HCV Mono-Infected Patients after DAA TherapyPathogens 2021; 10(11): 1488 doi: 10.3390/pathogens10111488
Xiaodong Shi, Lijia Yu, Yinglin Zhang, Zequan Liu, Huawei Zhang, Yansong Zhang, Ping Liu, Peishuang Du. Glycyrrhetinic acid alleviates hepatic inflammation injury in viral hepatitis disease via a HMGB1-TLR4 signaling pathwayInternational Immunopharmacology 2020; 84: 106578 doi: 10.1016/j.intimp.2020.106578
Georg Peschel, Jonathan Grimm, Christa Buechler, Manuela Gunckel, Kirstin Pollinger, Elisabeth Aschenbrenner, Sylvia Kammerer, Ernst-Michael Jung, Michael Haimerl, Jens Werner, Martina Müller, Kilian Weigand. Liver stiffness assessed by shear-wave elastography declines in parallel with immunoregulatory proteins in patients with chronic HCV infection during DAA therapyClinical Hemorheology and Microcirculation 2021; 79(4): 541 doi: 10.3233/CH-211193
Robert S. Wallis, Anne O’Garra, Alan Sher, Andreas Wack. Host-directed immunotherapy of viral and bacterial infections: past, present and futureNature Reviews Immunology 2023; 23(2): 121 doi: 10.1038/s41577-022-00734-z
Robert Wallis, Amit K. Srivastava, Andreas Wack, Charles A Knirsch. Textbook of SARS-CoV-2 and COVID-192024; : 52 doi: 10.1016/B978-0-323-87539-4.00003-8
Reem El-Shenawy, Sally Farouk, Naiera Helmy, Noha Bader El Din. Hepatitis C - Recent Advances2023;  doi: 10.5772/intechopen.1001057